Want to create an interactive transcript for this episode?
Podcast: Clinician's Roundtable
Episode: Targeting PIK3CA Mutations in HR+/HER2- Breast Cancer: New Insights from ReDiscover
Description:
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sarah Sammons, MD
About 40 percent of patients with metastatic HR+/HER2- breast cancer have an activating mutation in the PIK3CA gene,1,2 which plays a key role not only in tumor growth, but also in driving resistance to endocrine therapy.3-5 And while there are several FDA-approved PI3K pathway-targeted agents for patients with PIK3CA tumor mutations,6-8 they come with challenges, like modest efficacy and on-pathway effects.9-12 Given this unmet need, the ReDiscover trial evaluated the investigational agent RLY-2608 in combination with fulvestrant in in patients...